IVF
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B of -0.09 indicates the company's liabilities exceed its assets.
- Negative Price/Book ratio
- No P/E ratio due to lack of earnings
- Graham Number unavailable due to negative earnings/book value
Revenue growth is irrelevant if the company cannot cover its basic operating costs.
- 22.6% Revenue Growth
- Massive earnings misses
- Unsustainable operating margins
- Lack of capital to fund growth
The stock has effectively lost all its historical value.
- -99% 1Y return
- -100% 5Y return
- Consistent downward trend
The company is facing a severe solvency crisis.
- Debt/Equity is lower than sector average
- Piotroski F-Score 3/9 (Weak)
- Current Ratio 0.12 (Critical)
- ROA -48.36%
Company is in no position to return capital to shareholders.
- No dividend payments
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IVF and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IVF
INVO Fertility, Inc.
Primary
|
-100.0% | -100.0% | -99.0% | -93.2% | -53.3% | -19.9% |
|
HKPD
Cellyan Biotechnology Co., Ltd
Peer
|
-77.9% | -77.9% | -40.8% | -47.7% | -1.0% | +9.3% |
|
ICU
SeaStar Medical Holding Corporation
Peer
|
-99.8% | -99.3% | -70.8% | -35.1% | +33.9% | -13.9% |
|
BMGL
Basel Medical Group Ltd
Peer
|
-82.0% | -82.0% | -82.0% | -64.4% | +23.8% | -3.5% |
|
CYCN
Cyclerion Therapeutics, Inc.
Peer
|
-93.9% | -46.5% | +40.9% | +36.5% | +133.6% | +124.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IVF
INVO Fertility, Inc.
|
BEARISH | $13.99M | - | -% | -% | $2.01 | |
|
HKPD
Cellyan Biotechnology Co., Ltd
|
BEARISH | $14.62M | - | -13.4% | -4.3% | $0.62 | Compare |
|
ICU
SeaStar Medical Holding Corporation
|
BEARISH | $14.82M | - | -295.2% | -% | $3.71 | Compare |
|
BMGL
Basel Medical Group Ltd
|
BEARISH | $15.03M | - | -194.6% | -99.8% | $0.8 | Compare |
|
CYCN
Cyclerion Therapeutics, Inc.
|
BEARISH | $15.07M | - | -39.3% | -170.1% | $3.48 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-03 | SZOT MATTHEW K | Director | Sale | 4 | $6 |
Past News Coverage
Recent headlines mentioning IVF from our newsroom.